The estimated Net Worth of Amy Simon is at least $2.98 Millón dollars as of 1 July 2024. Amy Simon owns over 1,250 units of Beam Therapeutics stock worth over $1,659,577 and over the last 2 years Amy sold BEAM stock worth over $1,321,143.
Amy has made over 5 trades of the Beam Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently Amy sold 1,250 units of BEAM stock worth $29,100 on 1 July 2024.
The largest trade Amy's ever made was selling 23,687 units of Beam Therapeutics stock on 1 April 2024 worth over $734,771. On average, Amy trades about 5,609 units every 57 days since 2023. As of 1 July 2024 Amy still owns at least 68,805 units of Beam Therapeutics stock.
You can see the complete history of Amy Simon stock trades at the bottom of the page.
Amy's mailing address filed with the SEC is C/O BEAM THERAPEUTICS INC.,, 238 MAIN STREET, CAMBRIDGE, MA, 02142.
Over the last 5 years, insiders at Beam Therapeutics have traded over $63,012,019 worth of Beam Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Llc Fmr y Kristina Burow. On average, Beam Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $1,019,987. The most recent stock trade was executed by Amy Simon on 1 July 2024, trading 1,250 units of BEAM stock currently worth $29,100.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Beam Therapeutics executives and other stock owners filed with the SEC include: